This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van den Broeke, L. T. Articles by Berzofsky, J. A. Search for Related Content PubMed PubMed Citation Articles by van den Broeke, L. T. Articles by Berzofsky, J. A.

Identification and Epitope Enhancement of a PAX-FKHR Fusion Protein Breakpoint Epitope in Alveolar Rhabdomyosarcoma Cells Created by a Tumorigenic Chromosomal Translocation Inducing CTL Capable of Lysing Human Tumors

¹ Vaccine Branch and ² Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: Jay A. Berzofsky, Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Room 6B-04, Building 10, 10 Center Drive, Bethesda, MD 20892-1578. Phone: 301-496-6874; Fax: 301-496-9956; E-mail: berzofsk{at}helix.nih.gov.

Fusion proteins created by chromosomal translocations in tumors can create neoantigenic determinants at the breakpoint, which are unique to the tumor cells but shared by the vast majority of tumors of that histologic type. If the fusion protein is responsible for the malignant transformation, its expression cannot be lost by the tumor to escape immune responses against this tumor antigen. Here, we identify such a fusion protein breakpoint epitope in the PAX-FKHR fusion protein created by the t(2;13) translocation present in 80% of cases of alveolar rhabdomyosarcoma, a highly aggressive pediatric soft-tissue sarcoma. We use autologous dendritic cells pulsed with the RS10 breakpoint fusion peptide to raise a human CTL line from a normal healthy HLA-B7⁺ blood donor specific for this peptide. These CTLs are CD8⁺ (CD4^–CD56^–) and restricted by HLA-B7. These human peptide-specific CTL lyse human HLA-B7⁺ rhabdomyosarcoma tumor cells. Therefore, the fusion protein is endogenously processed to produce this natural epitope presented by HLA-B7 and thus this peptide is a bone fide human tumor antigen. We also define a substitution that increases the affinity for HLA-B7 without loss of antigenicity. This epitope-enhanced peptide may serve as a candidate cancer vaccine for HLA-B7⁺ patients with alveolar rhabdomyosarcoma. (Cancer Res 2006; 66(3): 1818-23)

This article has been cited by other articles:

				C. L. Mackall, E. H. Rhee, E. J. Read, H. M. Khuu, S. F. Leitman, D. Bernstein, M. Tesso, L. M. Long, D. Grindler, M. Merino, et al. A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas Clin. Cancer Res., August 1, 2008; 14(15): 4850 - 4858. [Abstract] [Full Text] [PDF]

				C. M. Linardic, S. Naini, J. E. Herndon II, C. Kesserwan, S. J. Qualman, and C. M. Counter The PAX3-FKHR Fusion Gene of Rhabdomyosarcoma Cooperates with Loss of p16INK4A to Promote Bypass of Cellular Senescence Cancer Res., July 15, 2007; 67(14): 6691 - 6699. [Abstract] [Full Text] [PDF]

				M. Sensi and A. Anichini Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy Clin. Cancer Res., September 1, 2006; 12(17): 5023 - 5032. [Abstract] [Full Text] [PDF]